An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer
Richard Junior Zapata Dongo, Julio A. Poterico, Diletta Fontana, Luca Mologni, Carla Alvarez-Chacon, Juan Rojas-Armas, Jaeson Calla
Research output: Contribution to journal › Original Article › peer-review
1Scopus
citations
Fingerprint
Dive into the research topics of 'An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer'. Together they form a unique fingerprint.